• Product NameSenicapoc
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivitySenicapoc is a potent inhibitor of the Gardos channel and ameliorates RBC dehydration in the SAD mouse. Senicapoc blocked Ca2+-induced rubidium flux from human RBCs with an IC50 value of 11 2 nM (CLT IC50 = 100 12 nM) and inhibited RBC dehydration with an IC50 of 30 20 nM. Senicapoc is in treatment of Sickle Cell Disease and Sickle Cell Anemia
• Target NamePotassium Channel inhibitor
• CAS No. 289656-45-7
• Calculated MW 323.11
• Formulation C20H15F2NO
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
  Pathways:Membrane transporter/Ion channel
  Receptor:Gardos channel
  Boling pt:
  Melting pt:
  Solubility:Chloroform
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Ataga KI, et al. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin Investig Drugs. 2009 Feb;18(2):231-9.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting